AbbVie
ABBV · NYSE
Bulios Fair Price
$190.39
27.6% downside
Current Price
$262.9
According to Bulios Fair Price, ABBV is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
AbbVie (ABBV) is a global pharmaceutical company specializing in the development and manufacturing of innovative medicines. Their portfolio includes drugs in the areas of immunology, oncology, neuroscience, and other therapeutic areas. With strong research and development capabilities, AbbVie offers a promising investment opportunity for long-term focused investors in the healthcare sector. Add ABBV stock to your watchlist on Bulios and stay informed about the latest news and innovations in the pharmaceutical industry.
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Robert A. Michael
Employees
57,000
Headquarters
North Chicago
Upcoming events
Ex-Dividend
Ex-dividend date
Earnings
Upcoming earnings report
Dividend Payment
Payment date